Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasiglucagon in Postprandial Hypoglycemia After Gastric Bypass
NCT03984370Phase 2Completed
- Sponsor
- Gentofte Hospital
- Start
- Sep 2019
- Primary completion
- Feb 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dasiglucagon in Postprandial hyperinsulinemic hypoglycemia (PHH) (3 arms), sponsored by Gentofte Hospital. Primary endpoint: Nadir plasma glucose concentration at 240 minutes. Started Sep 2019; status: completed.
02
Drugs
dasiglucagon
03
Conditions
Postprandial hyperinsulinemic hypoglycemia (PHH)
Beyond the preview
Go deeper on NCT03984370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03984370.